

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1633

KÄSLIN ET AL.

APPLICATION NO: 10/620,627

EXAMINER: LI, QUIAN JANICE

FILED: July 16, 2003

FOR: TRANSGENIC ANIMALS FOR STUDYING REGULATION OF

GENES

Mail Stop AF Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Novartis AG, a company organized under the laws of the Swiss Confederation, having a place of business at Lichtstrasse 35, Basel, Switzerland 4056, represents that it is the assignee and owner of the entire interest in the above-identified application by virtue of an assignment which was recorded in the United States Patent and Trademark Office on July 16, 2003 at Reel/Frame 014274/0460.

Novartis AG hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term defined in 35 USC §154-156 and §173 as shortened by any terminal disclaimer of U.S. Patent No. 6,632,978. U.S. Patent No. 6,632,978 is also assigned to Novartis AG by virtue of said assignment.

Novartis AG hereby agrees that any patent granted on the above-identified application shall be enforceable only for and during such period that it and said patent are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

08/31/2007 HVUDNG1 00000017 10620627

02 FC:1814

130.00 OP

In making the above disclaimer, Novartis AG does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 USC §154-156 and §173 of U.S. Patent No. 6,632,978, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

A terminal disclaimer fee under 37 CFR §1.20(d) is included.

Signed this 27th day of August, 2007 by the undersigned attorney of record.

DILWORTH & BARRESE, LLP 333 Earle Ovington Boulevard Uniondale, New York 11553 Tel. No. (516) 228-8484 Fax No. (516) 228-8516

ARP/ml

Ann R. Pokalsky

Registration No.: 34,697 Attorney for Applicants